85 related articles for article (PubMed ID: 17667601)
1. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G; De Braud F; Teresa Sandri M; Renne G; Zorzino L; Scardino E; Rocco B; Spitaleri G; De Pas T; Noberasco C; Nolè F; Verweij F; Matei V; De Cobelli O
Anticancer Drugs; 2007 Sep; 18(8):949-54. PubMed ID: 17667601
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
4. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Curigliano G; Pelosi G; De Pas T; Renne G; De Cobelli O; Manzotti M; Spitaleri G; de Braud F
Prostate; 2007 May; 67(6):603-4. PubMed ID: 17290443
[TBL] [Abstract][Full Text] [Related]
5. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
6. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
7. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
9. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Cury FL; Souhami L; Rajan R; Tanguay S; Gagnon B; Duclos M; Shenouda G; Faria SL; David M; Freeman CR
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):842-8. PubMed ID: 16289909
[TBL] [Abstract][Full Text] [Related]
12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
15. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Small EJ; Fontana J; Tannir N; DiPaola RS; Wilding G; Rubin M; Iacona RB; Kabbinavar FF
BJU Int; 2007 Oct; 100(4):765-9. PubMed ID: 17822457
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
20. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]